


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.21%
+1.88%
+3.92%
+1.04%
CRMD
CorMedix
$8.02
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Investors confidence is positive
CRMD Price Performance
$11.63 (-31.04%)
$11.54 (-30.50%)
$12.4 (-35.32%)
$10.44 (-23.18%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRMD Street Sentiment is bullish but have mixed views on the near-term outlook
CRMD has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
CRMD
CorMedix
8.02
+3.48%
NTAP
NetApp
98.33
-1.01%
AVGO
Broadcom
330.73
-0.75%
WB
10.83
-0.73%
NKE
Nike
62.60
+0.58%
What is CRMD current stock price?
What are CRMD stock strengths?
What is CRMD Risk Level?
What is CRMD market cap and volume?
What is CRMD current Stock IQ?
Should I buy CRMD stock right now?
Is CRMD a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRMD?
What does a 'Strong Sell' rating mean for CRMD?
What factors influence CRMD's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.21%
+1.88%
+3.92%
+1.04%
CRMD
CorMedix
Current Price
$8.02
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Investors confidence is positive
Recently Viewed
CRMD
CorMedix
8.02
+3.48%
NTAP
NetApp
98.33
-1.01%
AVGO
Broadcom
330.73
-0.75%
WB
10.83
-0.73%
NKE
Nike
62.60
+0.58%

CRMD Price Performance
$11.63 (-31.04%)
$11.54 (-30.50%)
$12.4 (-35.32%)
$10.44 (-23.18%)
CRMD Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRMD Street Sentiment is bullish but have mixed views on the near-term outlook
CRMD has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 19, 2025
Reiterate
Buy
D. Boral Capital
Dec 08, 2025
Upgrade
Buy
Zacks
Nov 14, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 13, 2025
Reiterate
Buy
Needham
Nov 13, 2025
Reiterate
Buy
D. Boral Capital
CRMD Stock IQ
CRMD Latest Analysis
Will CRMDS Bearish 2026 View Impact DefenCaths Long-Term Adoption?. CorMedixs DefenCath drives revenues with strong adoption but 2026 outlook signals slower growth raising concerns over long-term adoption.
Fri Jan 23, 2026
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?. CRMD and MIRM are advancing niche therapies with strong launches rising sales and strategic acquisitions shaping their growth.
Tue Jan 20, 2026
Witnessing An Insider Decision Joseph Todisco Exercises Options Valued At $93K At Cormedix. In a new SEC filing on January 20 it was revealed that Todisco Chief Executive Officer at CRMD) executed a significant exercise of company stock options.United States Securities and Exchange Commission. The transaction value amounted to $93784.Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company
Tue Jan 20, 2026
Will DefenCath Continue to Aid CorMedixs Top Line in Q4 Earnings?. CRMDs DefenCath the only FDA-approved antimicrobial catheter lock saw higher outpatient dialysis use in the fourth quarter likely driving revenues.
Thu Jan 15, 2026
Breaking Update: Steven Lefkowitz Engages In Options Exercise At Cormedix Realizing $22K. A large exercise of company stock options by CRMD) was disclosed in a new SEC filing on January 15 as part of an insider exercise.United States Securities and Exchange Commission Lefkowitz Board Member at Cormedix executed a strategic derivative sale. This involved exercising stock options for 15000 shares of CRMD resulting in a transaction value of $22275.The Thursday morning update indicates Cormedix Inc
Thu Jan 15, 2026
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Tue Jan 13, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRMD Stock trends
CRMD Stock performance
CRMD Stock analysis
CRMD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.